A comprehensive prognostic and immune analysis of LAPTM4B in pan-cancer and Philadelphia chromosome-positive acute lymphoblastic leukemia

doi:10.21203/rs.3.rs-4502403/v1

Download PDF

Research Article

A comprehensive prognostic and immune analysis of LAPTM4B in pan-cancer and Philadelphia chromosome-positive acute lymphoblastic leukemia

https://doi.org/10.21203/rs.3.rs-4502403/v1

This work is licensed under a CC BY 4.0 License

You are reading this latest preprint version

Lysosomal-associated protein transmembrane-4 beta (LAPTM4B) protein expression was increased in solid tumors, whereas few studies were performed in hematologic malignancies. We aimed to study the effect of the LAPTM4B gene in pan-cancer and Philadelphia chromosome-positive acute B cell lymphoblastic leukemia (Ph + B-ALL). The differential expression, diagnosis, prognosis, genetic and epigenetic alterations, tumor microenvironment, stemness, immune infiltration cells, function enrichment, single-cell analysis, and drug response across cancers were conducted based on multiple computational tools. Additionally, Ph + B-ALL transgenic mouse model with Laptm4b knockout was used to analyze the function of LAPTM4B in vivo. BrdU incorporation method, flow cytometry, and Witte-lock Witte culture were used to evaluate the roles of LAPTM4B in vitro. We identified that LAPTM4B expression was increased in various cancers, with significant associations with clinical outcomes. LAPTM4B expression correlated with DNA and RNA methylation patterns and was associated with drug resistance. It also influenced the tumor immune microenvironment, with implications for immunotherapy response. In leukemia, LAPTM4B was expressed in stem cells and associated with specific subtypes. Knockout of LAPTM4B impeded B-ALL progression in mice and reduced cell proliferation and caused G0/G1 arrest in vitro. Our study elucidated the role LAPTM4B that promoted the development and progression in Ph + B-ALL. Furthermore, LAPTM4B played a diagnostic, prognostic, and immunological factor.

LAPTM4B

Ph + B-ALL

pan-cancer

diagnosis

prognosis

Tumorigenesis is a multifaceted process influenced by a dynamic interplay between internal factors and the tumor microenvironment. Internal factors encompass genetic mutations, epigenetic changes, and the dysregulation of signaling pathways (Fujii et al., 2023; Fulton-Ward and Middleton, 2023). Tumor microenvironment is comprised of various factors including metabolomics, inflammation, angiogenesis, immune system modulation, extracellular matrix (ECM) (Berrell et al., 2023; Choi and Jung, 2023; Mempel et al., 2024; Sleeboom et al., 2024; Zhang et al., 2023). Crucially, membrane proteins play a pivotal role during tumorigenesis by facilitating the transmission of signals between the extracellular environment and the cell's interior (Lu et al., 2024). These proteins participate some fundamental cellular processes such as growth, differentiation, and survival (Lu et al., 2024; Malla et al., 2023; Wang et al., 2023). Therefore, investigating the intricate interplay between internal factors, the tumor microenvironment, and the role of membrane proteins is imperative for comprehending the intricacies of tumorigenesis. Such understanding lays the foundation for the development of targeted strategies aimed at preventing and treating cancer effectively. One of the research interests in our laboratory is to uncover the roles and mechanisms of membrane proteins in the initiation and development of tumors. Building upon the reported biological functions of lysosomal membrane-associated protein transmembrane-4 beta (LAPTM4B) in existing studies, we aim to comprehensively understand its involvement in cancer, especially Philadelphia chromosome-positive acute B cell lymphoblastic leukemia (Ph⁺ B-ALL).

LAPTM4B is recognized as a late endosomal protein, and it is also distributed in the plasma membrane. It exhibits widespread expression in various tissues throughout the body, with predominant levels observed in the heart, kidney, skeletal muscle, and hematopoietic stem cells (HSCs). In contrast, its expression is relatively lower in peripheral blood leukocytes, spleen, and thymus (Meng et al., 2016). LAPTM4B involves in multiple biological processes, including cell cycle, cell growth and proliferation, and autophagy. LAPTM4B interacts with and integrin and promotes cell growth and proliferation through a series of enzyme-linked reactions within the membrane (Peng et al., 2005). LAPTM4B also regulates cell cycle and engages in growth signaling pathways, such as PI3K/AKT and MAPK (Ji et al., 2022). LAPTM4B also promotes autophagy through the EGFR signaling pathway (Ji et al., 2022; Wu and Zhang, 2020), and loss of LAPTM4B inhibited later stages of autophagy by blocking maturation of the autophagosome (Li et al., 2011).

Increased LAPTM4B expression has been observed in various cancers, including breast, liver, lung, ovarian, uterine, and gastric cancers (Liao et al., 2023; Meng et al., 2016; Su et al., 2021; Wang et al., 2022). Notably, elevated LAPTM4B levels contribute to chemotherapy resistance in breast cancer. The overexpression of LAPTM4B induces resistance to anthracyclines (such as doxorubicin, daunorubicin, and epirubicin) by retaining the drug in the cytoplasm and reducing its nuclear localization, thereby diminishing drug-induced DNA damage (Li et al., 2010). In addition to solid tumors, LAPTM4B is also highly expressed in hematologic malignancies. LAPTM4B promoted AML progression by regulating the RPS9/STAT3 axis (Huang et al., 2023). Elevated LAPTM4B expression is associated with AML patients harboring NPM1 mutations in conjunction with FLT3-ITD mutations (Huang et al., 2012). In chronic myeloid leukemia (CML) bone marrow (BM) cells, LAPTM4B expression levels were significantly higher than those in normal individuals (Haferlach et al., 2010). Similar to observations in solid tumors, CML patients with higher LAPTM4B expression were associated with resistance to tyrosine kinase inhibitor (TKI) treatment (Singh et al., 2018).

Most studies on LAPTM4B have primarily focused on intracellular signaling in certain types of cancers, and a comprehensive understanding of LAPTM4B in tumorigenesis is still lacking. In this study, we aimed to elucidate the expression, clinical characteristics and immunological characteristics of LAPTM4B across various cancers. In particular, our investigation unveiled a significant correlation between LAPTM4B expression and survival outcomes in Ph⁺ B-ALL patients. Moreover, it was confirmed that the loss of the Laptm4b impeded BCR-ABL-induced B-ALL progression, both in vitro and in vivo.

Data Acquisition and analysis

The standardized pan-cancer dataset was downloaded from UCSC (https://xenabrowser.net/): TCGA TARGET GTEx (PANCAN, N = 19131, G = 60499). A log2(x + 1) transformation was applied to each expression value, and cancer types with fewer than 3 samples were excluded, resulting in the final expression data for 34 cancer types. Additionally, prognostic data for TCGA were sourced from prior studies (Liu et al., 2018). Simultaneously, TARGET follow-up data were supplemented from the UCSC database. Samples with a follow-up time of less than 30 days were excluded, and cancer types with fewer than 10 samples were also excluded. The abbreviations section provides the full names and corresponding abbreviations of the tumors.

The Ph⁺ B-ALL data was downloaded from the GEO database. RMA normalization was performed using the RMA algorithm the NimbleScan 2.5 software. The dataset GSE34861 comprises 191 adult B-ALL samples, among which 78 are Ph⁺ B-ALL samples.

Genetic and Epigenetic Alterations in Pan-cancer

Genomic alteration data and methylation data were download from cBioPortal database (https://www.cbioportal.org/). The correlation between LAPTM4B expression and gene promoter methylation was evaluated using Spearman rank correlation. Kaplan‒Meier analysis was performed to analyze the relationship between LAPTM4B methylation and the prognosis of patients.

Clinical Characteristics LAPTM4B in Pan-cancer

We developed the Cox proportional hazards regression model to analyze overall survival (OS), disease-specific survival (DSS), disease-free interval (DFI), and progression-free interval (PFI) of LAPTM4B across cancers. Kaplan‒Meier analysis was performed to analyze the prognostic significance.

The diagnostic significance of LAPTM4B across cancers was assessed by the Receiver Operator Characteristic (ROC) curve via “pROC” (v1.17.0.1). The diagnosis accuracy was evaluated by the Area under Curve (AUC). The AUC is closer to 1, the diagnosis accuracy is better.

The IC₅₀ values of various compounds in cancer cell lines were obtained from the GDSC dataset (https://www.cancerrxgene.org), to assess the relationship between DLAT and the drug response of tumor cells by the Spearman correlation coefficient. A higher IC50 indicates that cancers are less sensitive to the compounds.

Tumor immune microenvironment Analysis

Tumor-infiltrating lymphocytes (TILs) participated in predicting sentinel node status and associated with prognosis (Hall et al., 2016). ssGSEA scores of the correlation between LAPTM4B and immune cell infiltration for Ph⁺ B-ALL were calculated using the xCELL algorithm and TILs. Spearman rank correlation was employed to assess the association between LAPTM4B expression and immune cell infiltration in pan-cancer, utilizing the xCELL and CIBERSORT algorithms.

Immune checkpoint-related genes (ICGs) were obtained from a previous study (Hu et al., 2021). Immune-related genes were downloaded from the TISIDB database (http://cis.hku.hk/TISIDB/index.php). The relationship of immune-related genes and LAPTM4B in Ph⁺ B-ALL was evaluated using ssGSEA. Immune regulatory genes are distributed in five immune pathways, including chemokine (41 genes), receptor (18 genes), MHC (21 genes), immunoinhibitor (24 genes) and immunostimulator (46 genes). The relationship between immune-related genes and LAPTM4B expression in pan-cancer was evaluated by Spearman rank correlation.

Tumor Microenvironment Analysis in Pan-cancer

We obtained 10,180 tumor samples from a total of 44 tumor types for immune infiltration scores. ESTIMATE was used to reflect the degree of infiltration of stromal or immune cells into tumors. The ESTIMATE algorithm included stromal, immune, and ESTIMATE scores. Spearman rank correlation was used to evaluate the correlation between LAPTM4B expression and these three scores by the R software packages “estimate” and “psych”.

We downloaded all level 4 simple nucleotide variation data of TCGA samples from GDC (https://portal.gdc.cancer.gov/). Tumor mutation burden (TMB) was analyzed using MAftools package (Version 2.8.05) of R software. Tumor stem cell infiltration analysis was performed based on DNA methylation dry score (DNAss) and RNA dry score (RNAss) (Malta et al., 2018). Spearman rank correlation was used to evaluate the correlation between LAPTM4B expression and TMB, microsatellite instability (MSI), purity, DNAss and RNAss.

Single-cell Analysis and Enrichment Analysis

We conducted the single-cell level expression of LAPTM4B at in leukemia using TISCH2 (Han et al., 2023). TISCH2 encompasses 190 tumor scRNA sequence datasets with 6 million cells across 50 cancer types. To assess the functional and signaling aspects with LAPTM4B, we conducted Gene Set Enrichment Analysis (GSEA) on HALLMARK and KEGG pathways. Based on the median expression of LAPTM4B in cancer, the group was divided into high and low expression groups.

The Development of LAPTM4B Knockout Ph⁺ B-ALL Model and in vitro assay

The B6. LAPTM4B^loxp/loxp mice were generated at Biocytogen Pharmaceuticals (Beijing) Co., Ltd, which were intercrossed with B6.CMV-Cre mice to generate B6. LAPTM4B^−/− mice. BCR-ABL induced B-ALL model was developed as previously described (Hu et al., 2006). Briefly, bone marrow (BM) cells were collected from 8-week-old WT and LAPTM4B^−/− mice (n = 3) and resuspended with BCR/ABL viral infection medium, centrifugation at 1000g for 90min at 37 ℃, then cultured at 37 ℃ for 3 h. Then, viral transfected cells were injected into lethally irradicated recipient mice at a dosed of 1x10^5 B cells/mouse via the tail vein.

After the WT or LAPTM4B^−/− BM cells were transfected with BCR/ABL, then seeded in DMEM medium containing 10% FBS in 24-well plates at series initial cell numbers of 5x10^5 (500k), 3x10^5 (300k), 1x10^5 (100k), 3x10^4 (30k), 1x10^4 (10k), and 2.5x10^3 (2.5k). Each well cell numbers were adjusted to 1x10^6 cells/well with WT mice BM cells and cultured with DMEM medium containing 10% FBS. The cell number in eahc well was counted on day 7 post seeding.

Cell Cycle Experiments by the BrdU Incorporation Method

BrdU was added directly into the prepared cell medium at final concentration of 10 uM, and incubated for 1h. After collection and washing, cells were suspended with PBS containing 0.5% paraformaldehyde on ice for 20 minutes. Then cells were washed with PBS and resuspended with 70% ethanol overnight. Next day, after washing with PBS, cells were resuspended with 2N HCL/0.5% triton X-100 at room temperature for 20 min to denature. After neutralization with 0.1M sodium borate, cells were suspended with PBS containing 0.5% BSA and 0.5%Tween 20 and stained with anti-BrdU antibody-FitC (BD Biosciences) at room temperature for 20min. The cells were resuspended with PBS containing RNase and incubated at 37 ℃. After adding PI, cells were analyzed using flow cytometry.

Statistical Analysis

R software (version 4.2.1) was utilized for this analysis. The Wilcoxon's test and analysis of variance (ANOVA) were applied for comparisons involving two and multiple groups, respectively. Spearman correlation coefficient was employed for correlation analysis. All experiments were conducted in triplicate.

Expressions and Alterations of LAPTM4B in Human Cancers

In order to examine the expression profile of LAPTM4B in pan-cancers, we evaluated its expression across 34 cancer types using data from TCGA, TARGET, and GTEx databases. Our findings revealed high LAPTM4B expression in 28 cancer types compared to normal tissues, including glioblastoma (GBM), lower-grade glioma (LGG), uterine corpus endometrial carcinoma (UCEC), breast invasive carcinoma (BRCA), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), lung adenocarcinoma (LUAD), esophageal carcinoma (ESCA), stomach and esophageal carcinoma (STES), colon adenocarcinoma (COAD), colon adenocarcinoma/Rectum adenocarcinoma esophageal carcinoma (COADREAD), stomach adenocarcinoma (STAD), head and neck squamous cell carcinoma (HNSC), lung squamous cell carcinoma (LUSC), liver hepatocellular carcinoma (LIHC), high-risk Wilms tumor (WT), skin cutaneous melanoma (SKCM), bladder urothelial carcinoma (BLCA), thyroid carcinoma (THCA), rectum adenocarcinoma (READ), ovarian serous cystadenocarcinoma (OV), pancreatic adenocarcinoma (PAAD), testicular germ cell tumors (TGCT), uterine carcinosarcoma (UCS), acute lymphoblastic leukemia (ALL), acute myeloid leukemia (LAML), Adrenocortical carcinoma (ACC), and cholangiocarcinoma (CHOL). While, low LAPTM4B expression was observed in 4 cancer types, Pan-kidney cohort (KIPAN), prostate adenocarcinoma (PRAD), kidney renal clear cell carcinoma (KIRC), and kidney chromophobe (KICH) (Fig. 1A). Specifically, LAPTM4B exhibited high expression in BLCA, BRCA, CHOL, COAD, ESCA, HNSC, LIHC, LUAD, LUSC, READ, STAD, and UCEC, while showing low expression in KICH, KIRC, PRAD, and THCA compared to adjacent paired normal tissues (Fig. 1B). These results suggest that elevated LAPTM4B expression is associated with cancer progression in a majority of cases.

The amplification of LAPTM4B was observed most frequently in UCS, BRCA, BLCA, OV, PRAD, and LIHC, (Fig. 1C), and common in most cancers (Fig. 1C, D). Moreover, we found 34 mutation sites between amino acids 0 and 317, including 24 missense mutations, 2 truncating, 8 SV/fusion, and S265N as the most frequent mutation sites within LAPTM4B across cancers (Fig. 1E, F).

To elucidate potential associations between LAPTM4B and intracellular epigenetic alterations, we examined the status of genomic methylation and the expression of genes involved in mRNA methylation in various types of cancer cells using data from cBioPortal database. We found that there were significant negative correlations between LAPTM4B expression and gene promotor methylation in most tumors (Supplementary Fig. 1A). Increased methylation of LAPTM4B mRNA was related to poorer OS in patients with GBM and LGG (Supplementary Figure 1B, C). Furthermore, the relationships between LAPTM4B and genes involved in mRNA m1A, m5C, m6A modifications were evaluated. LAPTM4B expression was significantly positively related to these RNA modification genes in almost all tumors (Supplementary Figure 1D). These results indicated that LAPTM4B could influence tumor development by regulating the repair of RNA and DNA methylation in cancers.

The Clinical Features associated with LAPTM4B alterations in Pan-cancers

To evaluate the clinical significance of elevated LAPTM4B expression in various cancers, we conducted a Cox proportional hazards model analysis encompassing OS, DSS, DFI, and PFI. Univariate Cox regression analysis of OS, DSS, PFI, and DFI revealed that LAPTM4B served as a significant risk factor for patients in multiple cancer types, including LIHC, B-ALL, SARC, GBMLGG, SKCM, AML, ACC, UVM, CESC, HNSC, KICH, MESO, UVM, BRCA, and PCPG (Fig. 2A). Additionally, Kaplan‒Meier survival analyses of OS, DSS, and PFI were further explored across cancers (Fig. 2B-D).

The performance of the gene signature for diagnostic accuracy was evaluated by the ROC curves. Figure 3 showed that 17 types of cancer had high diagnostic accuracy (AUC > 0.9), including CHOL, ESCA, GBM, HNSC, LAML, LGG, LUAD, LUSC, OV, PAAD, READ, SKCM, STAD, TGCT, THYM, UCEC and UCS. These results suggested that LAPTM4B had good diagnostic value in a variety of cancers. The detailed results of all cancers were exhibited in the Supplementary table 1.

To assess the potential correlation between elevated LAPTM4B expression and the drug response of tumor cells, we conducted Spearman correlation coefficient analysis using data from the GDSC dataset. Our findings revealed increased LAPTM4B expression had increased IC50 values of 14 compounds, including rTRAIL, B-Raf inhibitors (PLX-4720, dabrafenib, SB590885), FTI-277 (FTase inhibitor), bexarotene (RXR agonist), dactolisib (PI3K/mTOR inhibitor), luminespib (HSP90 inhibitor), palbociclib (CDK4/6 inhibitor), (5Z)-7-Oxozeaenol (TAK1 inhibitor), QS11 (ARFGAP1 inhibitor), among others, which suggested that increased LAPTM4B lead drug resistance. Conversely, a negative association was observed with elesclomol and afatinib (EGFR/HER2 inhibitor) responses (Table 1). These results suggest that increased LAPTM4B expression may confer resistance to a broad spectrum of therapeutic agents in tumor cells. Moreover, we also found that LAPTM4B was positively correlated with RNAss and DNAss across most of the cancers (Supplementary Fig. 2A-B), which indicates that high expression of LAPTM4B might be associated with cancer tumor recurrence and metastasis.

Immune Status Analysis of LAPTM4B in Pan-Cancer

To explore the relationship between LAPTM4B expression and immune status in pan-cancer, we conducted a correlation analysis. Overall, we found that LAPTM4B expression was associated with immune subtypes in 19 cancer types and correlated with molecular subtypes in 14 cancer types (Supplementary Fig. 3A-B). Additionally, we analyzed stromal and immune cell scores to investigate the relationship between LAPTM4B expression and the tumor immune microenvironment (TIME) across cancers. We observed a positive correlation between LAPTM4B expression and StromalScore, ImmuneScore, and ESTIMATEScore in PAAD, OV, and UVM (Fig. 4A). While, LAPTM4B expression showed a negative correlation with these scores in GBM, LGG, LAML, BRCA, CESC, LUAD, STES, SARC, KIRP, KIPAN, STAD, LUSC, WT, SKCM, SKCM-M, THCA, NB, and TCGT (Fig. 4A). To explore the correlation between LAPTM4B expression and immune cells, we developed a heat map of LAPTM4B with immune cells by CIBERSORT and xCell. Our result revealed that LAPTM4B was associated with CD8⁺ T cells, macrophages M2 and Tregs in many cancers, which suggested that high LAPTM4B expression had inhibitory immune microenvironment (Fig. 4B-C). Overall, our findings suggested that elevated LAPTM4B expression might be associated with a potential decrease in patients' immune anti-tumor capabilities.

To investigate whether LAPTM4B expression levels are associated with TMB, MSI, and tumor purity, we conducted analyses using Spearman correlation analysis. The results showed that LAPTM4B expression was positively correlated with TMB in ACC, BRCA, GBMLGG, LAML, LGG, LUAD, PAAD, and THYM, while exhibiting a negative correlation in COAD, COADREAD, ESCA, PRAD, SKCM, and THCA (Fig. 5A). The MSI analysis revealed a positive correlation of LAPTM4B expression with MSI in KIPAN, TGCT, and UVM, while a negative correlation in COAD, COADREAD, DLBC, GBMLGG, LGG, PAAD, PRAD, and THCA (Fig. 5A). Additionally, LAPTM4B showed a significant correlation with tumor purity, with positive associations in CESC, ESCA, GBM, GBMLGG, HNSC, KIPAN, KIRP, LGG, LUAD, LUSC, SARC, SKCM, STAD, STES, TGCT, and THYM, and negative associations in BLCA, LIHC, OV, PCPG, PRAD, UCS, and UVM (Figs. 5A). These findings suggest that LAPTM4B expression might serve as a potential biomarker for immunotherapy.

Subsequently, the correlations of expression levels between LAPTM4B and immune checkpoint genes and immune regulatory genes in cancers were also investigated. We found that LAPTM4B expression was positively related to immune regulatory genes in majority tumor types, especially in PRAD, UVM, THYM, LIHC, BLCA, and OV. While, LAPTM4B expression was negatively related to immune regulatory genes in TGCT, GBM, LUAD, SARC, KIPAN, and SKCM (Fig. 5B). Additionally, LAPTM4B expression was positively related to immune checkpoint genes in most types of tumors, except for some tumors, which were mainly TGCT, GBM, SKCM, and SARC (Fig. 5C). In general, these results suggested that LAPTM4B might regulate immune cell infiltration and immune-related genes functions in most tumor types.

Single-cell and Enrichment Analysis of LAPTM4B Expression in Leukemia

To specifically and deeply depict the pictures of LAPTM4B involving in malignancies, then we focused on hematological malignancies, particularly Ph⁺ B-ALL, to elucidate and clarify the biological functional characteristics of LAPTM4B in tumors. Taking the advantages of single-cell sequencing and open public data, we found that LAPTM4B was expressed mainly in normal HSCs, progenitors, and AML cells (Fig. 6A-B). In an ALL sample, we found that LAPTM4B was highly expressed in proerythroblasts, but not malignant cells (Fig. 6C-D). Interesting, an analysis based on an expression profiling of 191 B-ALL samples and 3 normal pre-B samples showed that LAPTM4B was more highly expressed in BCR/ABL B-ALL than other subtypes (Fig. 6E). Then, we performed the analysis of the function and pathways of LAPTM4B-related genes in Ph⁺ B-ALL. We found that genes associated with HSCs and leukemia stem cells (LSCs) were up-enriched in high LAPTM4B expression samples (Fig. 6F-G), as well as genes associated with cell cycle, DNA replication, MYC target, E2F and G2M checkpoint pathways were also up-enriched in in Ph⁺ B-ALL (Fig. 6H-I).

LAPTM4B deletion impairs the development and progression of Ph⁺ B-ALL

To instigate the involvement of LAPTM4B in the development of Ph⁺ B-ALL, we employed a Ph⁺ B-ALL mouse model. Bone marrow (BM) cells from wild type (WT) or LAPTM4B^−/− mice were transfected with retrovirus containing BCR/ABL and then injected into lethally irradicated recipients (Fig. 7A). Overall, the survival time of recipients receiving LAPTM4B^−/− BM cells was significantly longer than that receiving WT BM cells (Fig. 7B). We also monitored the number of leukemic cells with BCR/ABL (represented with GFP and B220) in peripheral blood of mice receiving BCR/ABL-transduced WT or LAPTM4B^−/− BM cells on the day 10, 20 and 30 post-BM transplantation. We found that the percentages of B-lymphoid leukemic cells were significantly lower in mice receiving BCR/ABL-transduced WT or LAPTM4B^−/− BM cells than in those receiving BCR/ABL-transduced WT BM cells at all time points measured (Fig. 7C). To investigate the role of LAPTM4B in BCR/ABL-induced leukemogenesis, we conducted an in vitro assay for proliferation of BCR/ABL transformed BM B-lymphoid progenitors, as described in methods. BCR-ABL-transformed B-lymphoid progenitors from LAPTM4B^−/− BM cells exhibited much lower number than it transformed those from WT BM cells (Fig. 7D). Further, in vitro Brdu assays for cell proliferation rate showed that LAPTM4B deletion impaired Ph⁺ B-ALL cell proliferation and caused G0/G1 arrest (Fig. 7E). These findings demonstrated that LAPTM4B deletion significantly impaired the development and progression of Ph⁺ B-ALL.

Relationships between LAPTM4B Expression and Immune Status in Ph⁺ B-ALL

To evaluate the association of LAPTM4B expression with TME in Ph⁺ B-ALL, we conducted an ESTIMATE analysis to calculate the stromal score, immune score, ESTIMATE score, and tumor purity within Ph⁺ B-ALL. We found that LAPTM4B expression was not significantly associated with TME in Ph⁺ B-ALL (Supplementary Fig. 4). Then, the relationship between LAPTM4B and immune cells in Ph⁺ B-ALL was conducted using xCell algorithm method. The scores of CD4⁺ memory T cells, CD8⁺ T cells, HSC, preadipocytes, and Tgd cells were higher; while, the scores of CD4⁺ Tem, eosinophils, epithelial cells, MSC, and NKT were significantly lower in the high LAPTM4B expression patient samples (Fig. 8A). LAPTM4B expression was negatively related to macrophages M2, NKT, mv endothelial cells, and CD4⁺ Tem; while they were positively correlated with CD4⁺ memory T cells, Th2 cells, Tgd cells, CD4⁺ T cells and microenvironment Score (Fig. 8B). Moreover, immune infiltration scores of tumor-infiltrating lymphocytes (TILs) type in different LAPTM4B expression groups were also evaluated using ssGSEA. The central memory CD4 T cells, effector memory CD4 T cells, immature B cells, plasmacytoid dendritic cells, and immature dendritic cells were highly expressed in the high LAPTM4B expression patient samples (Fig. 8C).

The correlation between LAPTM4B expression and immune-related genes was also assessed. As previous reports, there were 79 genes related to immune checkpoint (Hu et al., 2021). We found that TNFRSF14 and TNFSF14 were lowly expressed in the high LAPTM4B expression samples (Supplementary Fig. 5A). Additionally, TNFRSF14 was negatively correlated with LAPTM4B expression; whereas, CTLA4, HLA-E, and ICOS were positively associated with LAPTM4B expression (Supplementary Fig. 5B). Moreover, the correlation between LAPTM4B and the chemokine genes was also evaluated. We found that CCL1, CCL11, CCL15, CCL19, CCL21, CCL22, CCL24 and CCL25 were lowly expressed in high LAPTM4B expression samples (Supplementary Fig. 5C). But, no significant difference was observed on immunoinhibitory genes, immunostimulatory genes, receptor genes, and MHC genes except for IL6, LTA, ULBP1, and XCR1 (Supplementary Fig. 6A-D). These results suggested that the high expression of LAPTM4B might affected immune microenvironment in Ph⁺ B-ALL.

LAPTM4B is required for lysosomes function, participates in the cell death program, promotes autophagy and tolerance to metabolic stress in cancer cells (Vergarajauregui et al., 2011) (Blom et al., 2015), and is an essential gene for adjuvant drug resistance(Li et al., 2012; Li et al., 2011). Our results revealed the role LAPTM4B plays in pan-cancer and Ph⁺ B-ALL. We determined the expression levels of LATPM4B mRNA in various cancers, and confirmed the most common types of LAPTM4B mutations and their locations. The correlation between epigenetic alterations and LAPTM4B were evaluated. We also assessed the diagnostic, prognostic and therapeutic values of LAPTM4B expression across cancers and differentiated its expression levels across several immune and cellular subtypes of cancers. We associated LAPTM4B expression levels with tumor microenvironment and the infiltration levels of immune cells and genes in various cancers. Besides, the expression of LAPTM4B at the single-cell level and function in B-ALL were explored. We identified that the loss of the LAPTM4B gene impeded BCR-ABL-induced B-ALL progression, both in vitro and in vivo. We also explored the immunological function of LAPTM4B in Ph⁺ B-ALL.

LAPTM4B was not highly expressed in all tissues, while we found that it was highly expressed in most cancers. And the amplification was the most frequent alteration. However, the expression of LAPTM4B was discovered lowly expressed in KIPAN, KIRC, KICH and PRAD, while the genetic alterations were mainly amplification in these cancers. Therefore, there were other factors affected the expression of LAPTM4B. As we known, abnormal methylation of DNA and RNA promotes various diseases and cancers (Jones and Baylin, 2007; Klutstein et al., 2016; Li et al., 2022; Qu et al., 2022; Xu et al., 2023; Zhao et al., 2023; Zhao et al., 2017). And we found that LAPTM4B expression was significantly related to DNA methylation and RNA modifications in these cancers. Theses might partly explain the inconsistencies between alteration and expression.

A total of 17 types of cancer had high diagnostic accuracy (AUC > 0.9), suggesting that LAPTM4B had good diagnostic value. Meanwhile, LAPTM4B was a risk factor in many cancers. Besides, we found that increased LAPTM4B expression led resistance to a broad spectrum of therapeutic agents in tumor cells. These results were consistent with previous studies that LAPTM4B could be a diagnostic, prognostic and therapeutic factor in hepatocellular carcinoma, breast cancer, hepatocellular carcinoma, bladder cancer and renal cell carcinoma and so on (Dong et al., 2017; Gan et al., 2023; Maki et al., 2015; Meng et al., 2018; Ren et al., 2021; Su et al., 2021; Wang et al., 2019; Wang et al., 2022; Yang et al., 2018; Yang et al., 2019; Zhong et al., 2021). LAPTM4B expression was different in different molecular or immune subtypes of cancer, which results in different survival in the overall population and particular subtype of cancer. Therefore, immune features should be also considered in the further study.

TMB can reflect the proportion of somatic mutations in tumors (Choucair et al., 2020). MSI refers to the arbitrary length change of microsatellites in tumor tissue due to insertion or deletion of repeat units (Bonneville et al., 2017). The purity of the tumor usually related to prognosis (Thorsson et al., 2018). TMB, MSI, and tumor purity are emerging biomarkers associated with the immunotherapy response. ESTIMATE reflects the degree of infiltration of stromal or immune cells into tumors. High stemness scores represent the activity of tumor stem cells, and are associated with drug resistance and the continuous proliferation of tumor cells, and are correlated with poorer survival (Malta et al., 2018). Our results exhibited that LAPTM4B was significant correlated with these indexs. Besides, we showed that LAPTM4B was related to different immune cells in various cancers. In general, the infiltration of activated CD8⁺ T cells, Tem and Tcm CD8 + cells, and Tem CD4 + cells was associated with good prognosis, whereas MDSCs and Tregs were correlated with bad prognosis (Charoentong et al., 2017). A previous study identified that LAPTM4B inhibited human regulatory T cells produced TGF-β1 (Huygens et al., 2015). Besides, LAPTM4B was upregulated in CML TKI-resistant patients (Singh et al., 2018). Therefore, LAPTM4B might be an immunotherapeutic factor in various cancers.

Then, we found that LAPTM4B is expressed primarily in stem cells at single-cell level in leukemia, and highly expressed in BCR/ABL subtype of B-ALL, and upregulated stem cell pathway in Ph⁺ B-ALL. A previous study also identified LAPTM4B as a candidate gene related to stemness, which was the downstream target of HOXB4 in hematopoietic progenitor cells (Lee et al., 2010). Similarly, the study verified that LAPTM4B was closely related to the stemness of HCC (Liao et al., 2023). These studies illustrated that LAPTM4B might regulate stem cell-related genes. Additionally, LAPTM4B might participated in the signaling pathways of MYC, E2F, cell cycle, and T/B cell receptor. And in the Ph + B-ALL mouse model, LAPTM4B knockout prolonged survival, inhibited cell proliferation and arrest of G0/G1. The results were similar to the previous study, which exhibited that LAPTM4B promoted the entry of cells from the G1 into the S phase in breast cancer (Tao et al., 2019).

In B-cell malignancies, leukemic cells can alter the normal microenvironment, in favor of their growth, survival and resistance to cytotoxic therapies (Hughes et al., 2022). Immune cells are important constituents of the tumor stroma and play a crucial role in tumor development and progression60 (Hinshaw and Shevde, 2019; Lei et al., 2020). Our study showed that LAPTM4B expression was associated with HSC, preadipocytes, immature B cells, and immature dendritic cells in Ph + B-ALL. These results validated that LAPTM4B was related to stem cell pathways as before analyzed. Moreover, the results demonstrated that high LAPTM4B expression had low TNFRSF14 and TNFSF14 expression, and was positively correlated with the CTLA4 and ICOS checkpoint gene. TNFSF14 was an immune-activating gene, mainly expressed in activated T cells, activated natural killer cells and immature dendritic cells (Ware and Sedý). TNFRSF14 is a receptor for BTLA, TNFSF14/LIGHT, and homotrimeric TNFSF1, is involved in lymphocyte activation. CTLA4 also known as CD152, is a protein receptor that acts as an immune checkpoint and negatively regulates the immune response (Patwekar et al.). ICOS, also called CD278, ICOS were immune checkpoint proteins expressed on activated T cells. Tumor-infiltrating Tregs expressed high levels of cell surface molecules associated with T-cell activation, such as CTLA4, PD-1, LAG3, TIGIT, ICOS, and TNF receptor superfamily members (Li et al.). These results suggested that LAPTM4B might influence the efficacy of immunotherapy.

In summary, our study systematically performed a comprehensive pan-cancer analysis of LAPTM4B, and explored the expression, immunological features, and functions of the LAPTM4B gene in the Ph⁺ B-ALL mouse model. We demonstrated the abnormal expression profiles of LAPTM4B and it was related to clinical diagnosis, prognosis, genetic and epigenetic alterations, immunological features, and drug response. Additionally, we identified that increased LAPTM4B expression was associated with an unfavorable prognosis and promoted the development and progression in Ph⁺ B-ALL, and was related to immune status. These results could help illustrate the underlying oncogenic role and immunological function of LAPTM4B in cancers.

Competing Interests

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Authors’ Contributions

HZ and YY have contributed equally to this work and share the first authorship. HZ and YY participated in the study design and wrote the manuscript. HZ and YY acquired the data, and analysed and interpreted the data. YY, WH, LZ and HZ performed the experiments. YH and TN revised the manuscript. All authors contributed to the manuscript and approved the submitted version.

Funding

This work was supported by Natural Science Foundation of Sichuan Province (NO. 24NSFSC3632), 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University (No. ZYJC21007), National Key Research and Development Program of China (No. 2022YFC2502600, 2022YFC2502603), and National Natural Science Foundation of China (No. 82370192).

Data availability statements

Not applicable.

Ethics approval

The animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC), West China Hospital, Sichuan University. All animal experimental procedures were conducted in accordance with the Regulations for the Administration of Affairs Concerning Experimental Animals approved by the State Council of People’s Republic of China.

Acknowledgments

The authors acknowledge the databases in this article for providing their platforms and those contributors for uploading their valuable datasets.

Berrell, N., Sadeghirad, H., Blick, T., Bidgood, C., Leggatt, G.R., O'Byrne, K., and Kulasinghe, A. (2023). Metabolomics at the tumor microenvironment interface: Decoding cellular conversations. Medicinal research reviews.
Blom, T., Li, S., Dichlberger, A., Bäck, N., Kim, Y.A., Loizides-Mangold, U., Riezman, H., Bittman, R., and Ikonen, E. (2015). LAPTM4B facilitates late endosomal ceramide export to control cell death pathways. Nature chemical biology 11, 799-806.
Bonneville, R., Krook, M.A., Kautto, E.A., Miya, J., Wing, M.R., Chen, H.Z., Reeser, J.W., Yu, L., and Roychowdhury, S. (2017). Landscape of Microsatellite Instability Across 39 Cancer Types. JCO precision oncology 2017.
Charoentong, P., Finotello, F., Angelova, M., Mayer, C., Efremova, M., Rieder, D., Hackl, H., and Trajanoski, Z. (2017). Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade. Cell Reports 18, 248-262.
Choi, Y., and Jung, K. (2023). Normalization of the tumor microenvironment by harnessing vascular and immune modulation to achieve enhanced cancer therapy. Experimental & molecular medicine 55, 2308-2319.
Choucair, K., Morand, S., Stanbery, L., Edelman, G., Dworkin, L., and Nemunaitis, J. (2020). TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials. Cancer gene therapy 27, 841-853.
Dong, X., Tamura, K., Kobayashi, D., Ando, N., Sumita, K., and Maehara, T. (2017). LAPTM4B-35 is a novel prognostic factor for glioblastoma. Journal of neuro-oncology 132, 295-303.
Fujii, M., Sekine, S., and Sato, T. (2023). Decoding the basis of histological variation in human cancer. Nature reviews Cancer.
Fulton-Ward, T., and Middleton, G. (2023). The impact of genomic context on outcomes of solid cancer patients treated with genotype-matched targeted therapies: a comprehensive review. Annals of oncology : official journal of the European Society for Medical Oncology 34, 1113-1130.
Gan, X., Li, S., Wang, Y., Du, H., Hu, Y., Xing, X., Cheng, X., Yan, Y., and Li, Z. (2023). Aspartate β-Hydroxylase Serves as a Prognostic Biomarker for Neoadjuvant Chemotherapy in Gastric Cancer. International journal of molecular sciences 24.
Haferlach, T., Kohlmann, A., Wieczorek, L., Basso, G., Kronnie, G.T., Béné, M.C., De Vos, J., Hernández, J.M., Hofmann, W.K., Mills, K.I., et al. (2010). Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 28, 2529-2537.
Hall, M., Liu, H., Malafa, M., Centeno, B., Hodul, P.J., Pimiento, J., Pilon-Thomas, S., and Sarnaik, A.A. (2016). Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors. Journal for immunotherapy of cancer 4, 61.
Han, Y., Wang, Y., Dong, X., Sun, D., Liu, Z., Yue, J., Wang, H., Li, T., and Wang, C. (2023). TISCH2: expanded datasets and new tools for single-cell transcriptome analyses of the tumor microenvironment. Nucleic acids research 51, D1425-d1431.
Hinshaw, D.C., and Shevde, L.A. (2019). The Tumor Microenvironment Innately Modulates Cancer Progression. Cancer research 79, 4557-4566.
Hu, F.F., Liu, C.J., Liu, L.L., Zhang, Q., and Guo, A.Y. (2021). Expression profile of immune checkpoint genes and their roles in predicting immunotherapy response. Briefings in bioinformatics 22.
Hu, Y., Swerdlow, S., Duffy, T.M., Weinmann, R., Lee, F.Y., and Li, S. (2006). Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proceedings of the National Academy of Sciences of the United States of America 103, 16870-16875.
Huang, L., Zhou, K., Yang, Y., Shang, Z., Wang, J., Wang, D., Wang, N., Xu, D., and Zhou, J. (2012). FLT3-ITD-associated gene-expression signatures in NPM1-mutated cytogenetically normal acute myeloid leukemia. International journal of hematology 96, 234-240.
Huang, Y., Peng, M., Qin, H., Li, Y., Pei, L., Liu, X., and Zhao, X. (2023). LAPTM4B promotes AML progression through regulating RPS9/STAT3 axis. Cellular signalling 106, 110623.
Hughes, A.M., Kuek, V., Kotecha, R.S., and Cheung, L.C. (2022). The Bone Marrow Microenvironment in B-Cell Development and Malignancy. Cancers 14.
Huygens, C., Liénart, S., Dedobbeleer, O., Stockis, J., Gauthy, E., Coulie, P.G., and Lucas, S. (2015). Lysosomal-associated Transmembrane Protein 4B (LAPTM4B) Decreases Transforming Growth Factor β1 (TGF-β1) Production in Human Regulatory T Cells. The Journal of biological chemistry 290, 20105-20116.
Ji, X., Ma, H., and Du, Y. (2022). Role and mechanism of action of LAPTM4B in EGFR-mediated autophagy. Oncology letters 23, 109.
Jones, P.A., and Baylin, S.B. (2007). The epigenomics of cancer. Cell 128, 683-692.
Klutstein, M., Nejman, D., Greenfield, R., and Cedar, H. (2016). DNA Methylation in Cancer and Aging. Cancer research 76, 3446-3450.
Lee, H.M., Zhang, H., Schulz, V., Tuck, D.P., and Forget, B.G. (2010). Downstream targets of HOXB4 in a cell line model of primitive hematopoietic progenitor cells. Blood 116, 720-730.
Lei, X., Lei, Y., Li, J.K., Du, W.X., Li, R.G., Yang, J., Li, J., Li, F., and Tan, H.B. (2020). Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy. Cancer letters 470, 126-133.
Li, M., Tao, Z., Zhao, Y., Li, L., Zheng, J., Li, Z., and Chen, X. (2022). 5-methylcytosine RNA methyltransferases and their potential roles in cancer. Journal of translational medicine 20, 214.
Li, Q., Lu, J., Li, J., Zhang, B., Wu, Y., and Ying, T. Antibody-based cancer immunotherapy by targeting regulatory T cells.
Li, Y., Iglehart, J.D., Richardson, A.L., and Wang, Z.C. (2012). The amplified cancer gene LAPTM4B promotes tumor growth and tolerance to stress through the induction of autophagy. Autophagy 8, 273-274.
Li, Y., Zhang, Q., Tian, R., Wang, Q., Zhao, J.J., Iglehart, J.D., Wang, Z.C., and Richardson, A.L. (2011). Lysosomal transmembrane protein LAPTM4B promotes autophagy and tolerance to metabolic stress in cancer cells. Cancer research 71, 7481-7489.
Li, Y., Zou, L., Li, Q., Haibe-Kains, B., Tian, R., Li, Y., Desmedt, C., Sotiriou, C., Szallasi, Z., Iglehart, J.D., et al. (2010). Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nature medicine 16, 214-218.
Liao, J., Wang, J., Xu, Y., Wu, Y., Wang, M., Zhao, Q., Tan, X., Meng, Y., Wei, L., and Huang, A. (2023). LAPTM4B-YAP loop feedback amplification enhances the stemness of hepatocellular carcinoma. iScience 26, 106754.
Liu, J., Lichtenberg, T., Hoadley, K.A., Poisson, L.M., Lazar, A.J., Cherniack, A.D., Kovatich, A.J., Benz, C.C., Levine, D.A., Lee, A.V., et al. (2018). An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell 173, 400-416.e411.
Lu, S., Gan, L., Lu, T., Zhang, K., Zhang, J., Wu, X., Han, D., Xu, C., Liu, S., Yang, F., et al. (2024). Endosialin in Cancer: Expression Patterns, Mechanistic Insights, and Therapeutic Approaches. Theranostics 14, 379-391.
Maki, Y., Fujimoto, J., Lang, W., Xu, L., Behrens, C., Wistuba, II, and Kadara, H. (2015). LAPTM4B is associated with poor prognosis in NSCLC and promotes the NRF2-mediated stress response pathway in lung cancer cells. Scientific reports 5, 13846.
Malla, R., Marni, R., and Chakraborty, A. (2023). Exploring the role of CD151 in the tumor immune microenvironment: Therapeutic and clinical perspectives. Biochimica et biophysica acta Reviews on cancer 1878, 188898.
Malta, T.M., Sokolov, A., Gentles, A.J., Burzykowski, T., Poisson, L., Weinstein, J.N., Kamińska, B., Huelsken, J., Omberg, L., Gevaert, O., et al. (2018). Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Cell 173, 338-354.e315.
Mempel, T.R., Lill, J.K., and Altenburger, L.M. (2024). How chemokines organize the tumour microenvironment. Nature reviews Cancer 24, 28-50.
Meng, Y., Wang, L., Chen, D., Chang, Y., Zhang, M., Xu, J.J., Zhou, R., and Zhang, Q.Y. (2016). LAPTM4B: an oncogene in various solid tumors and its functions. Oncogene 35, 6359-6365.
Meng, Y., Wang, L., Xu, J., and Zhang, Q. (2018). AP4 positively regulates LAPTM4B to promote hepatocellular carcinoma growth and metastasis, while reducing chemotherapy sensitivity. Molecular oncology 12, 373-390.
Patwekar, M., Sehar, N., Patwekar, F., Medikeri, A., Ali, S., Aldossri, R.M., and Rehman, M.U. Novel immune checkpoint targets: A promising therapy for cancer treatments.
Peng, C., Zhou, R.L., Shao, G.Z., Rui, J.A., Wang, S.B., Lin, M., Zhang, S., and Gao, Z.F. (2005). Expression of lysosome-associated protein transmembrane 4B-35 in cancer and its correlation with the differentiation status of hepatocellular carcinoma. World journal of gastroenterology 11, 2704-2708.
Qu, X., Zhang, Y., Sang, X., Ren, D., Zhao, H., and Wong, S.T.C. (2022). Methyladenosine Modification in RNAs: From Regulatory Roles to Therapeutic Implications in Cancer. Cancers 14.
Ren, Y., Hu, K., Bi, L., Wu, H., Li, Y., Han, Y., Zhou, W., Li, H., Jin, H., and Wu, H. (2021). Noninvasively visualize the expression of LAPTM4B protein using a novel (18)F-labeled peptide PET probe in hepatocellular carcinoma. Nuclear medicine and biology 100-101, 52-60.
Singh, N., Tripathi, A.K., Sahu, D.K., Mishra, A., Linan, M., Argente, B., Varkey, J., Parida, N., Chowdhry, R., Shyam, H., et al. (2018). Differential genomics and transcriptomics between tyrosine kinase inhibitor-sensitive and -resistant BCR-ABL-dependent chronic myeloid leukemia. Oncotarget 9, 30385-30418.
Sleeboom, J.J.F., van Tienderen, G.S., Schenke-Layland, K., van der Laan, L.J.W., Khalil, A.A., and Verstegen, M.M.A. (2024). The extracellular matrix as hallmark of cancer and metastasis: From biomechanics to therapeutic targets. Science translational medicine 16, eadg3840.
Su, Q., Luo, H., Zhang, M., Gao, L., and Zhao, F. (2021). LAPTM4B promotes the progression of nasopharyngeal cancer. Bosnian journal of basic medical sciences 21, 305-312.
Tao, D., Liang, J., Pan, Y., Zhou, Y., Feng, Y., Zhang, L., Xu, J., Wang, H., He, P., Yao, J., et al. (2019). In Vitro and In Vivo Study on the Effect of Lysosome-associated Protein Transmembrane 4 Beta on the Progression of Breast Cancer. Journal of breast cancer 22, 375-386.
Thorsson, V., Gibbs, D.L., Brown, S.D., Wolf, D., Bortone, D.S., Ou Yang, T.H., Porta-Pardo, E., Gao, G.F., Plaisier, C.L., Eddy, J.A., et al. (2018). The Immune Landscape of Cancer. Immunity 48, 812-830.e814.
Vergarajauregui, S., Martina, J.A., and Puertollano, R. (2011). LAPTMs regulate lysosomal function and interact with mucolipin 1: new clues for understanding mucolipidosis type IV. Journal of cell science 124, 459-468.
Wang, C., Zhang, Y., Chen, W., Wang, Y., and Xing, D. (2023). Epidermal growth factor receptor PROTACs as an effective strategy for cancer therapy: A review. Biochimica et biophysica acta Reviews on cancer 1878, 188927.
Wang, L., Meng, Y., and Zhang, Q.Y. (2019). LAPTM4B is a novel diagnostic and prognostic marker for lung adenocarcinoma and associated with mutant EGFR. BMC cancer 19, 293.
Wang, L., Wang, Y., and Zhang, Q. (2022). Serum LAPTM4B as a Potential Diagnostic and Prognostic Biomarker for Breast Cancer. BioMed research international 2022, 6786351.
Ware, C.F., and Sedý, J.R. TNF Superfamily Networks: bidirectional and interference pathways of the herpesvirus entry mediator (TNFSF14).
Wu, M., and Zhang, P. (2020). EGFR-mediated autophagy in tumourigenesis and therapeutic resistance. Cancer letters 469, 207-216.
Xu, X., Peng, Q., Jiang, X., Tan, S., Yang, Y., Yang, W., Han, Y., Chen, Y., Oyang, L., Lin, J., et al. (2023). Metabolic reprogramming and epigenetic modifications in cancer: from the impacts and mechanisms to the treatment potential. Experimental & molecular medicine 55, 1357-1370.
Yang, Y., Xu, J., and Zhang, Q. (2018). Detection of urinary survivin using a magnetic particles-based chemiluminescence immunoassay for the preliminary diagnosis of bladder cancer and renal cell carcinoma combined with LAPTM4B. Oncology letters 15, 7923-7933.
Yang, Z., Senninger, N., Flammang, I., Ye, Q., and Dhayat, S.A. (2019). Clinical impact of circulating LAPTM4B-35 in pancreatic ductal adenocarcinoma. Journal of cancer research and clinical oncology 145, 1165-1178.
Zhang, Z., Li, X., Wang, Y., Wei, Y., and Wei, X. (2023). Involvement of inflammasomes in tumor microenvironment and tumor therapies. Journal of hematology & oncology 16, 24.
Zhao, A., Zhou, H., Yang, J., Li, M., and Niu, T. (2023). Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies. Signal transduction and targeted therapy 8, 71.
Zhao, B.S., Roundtree, I.A., and He, C. (2017). Post-transcriptional gene regulation by mRNA modifications. Nature reviews Molecular cell biology 18, 31-42.
Zhong, H., Yuan, C., He, J., Yu, Y., Jin, Y., Huang, Y., and Zhao, R. (2021). Engineering Peptide-Functionalized Biomimetic Nanointerfaces for Synergetic Capture of Circulating Tumor Cells in an EpCAM-Independent Manner. Analytical chemistry 93, 9778-9787.

Download PDF

Reviewers invited by journal
24 Jul, 2024
Editor assigned by journal
09 Jul, 2024
First submitted to journal
09 Jul, 2024

You are reading this latest preprint version

A comprehensive prognostic and immune analysis of LAPTM4B in pan-cancer and Philadelphia chromosome-positive acute lymphoblastic leukemia

Status:

Version 1

Abstract

Figures

Introduction

Materials and Methods

Data Acquisition and analysis

Genetic and Epigenetic Alterations in Pan-cancer

Tumor immune microenvironment Analysis

Tumor Microenvironment Analysis in Pan-cancer

Single-cell Analysis and Enrichment Analysis

Cell Cycle Experiments by the BrdU Incorporation Method

Statistical Analysis

Results

Discussion

Declarations

References

Supplementary Files

Status:

Version 1